Xprochem is a biotech company at the forefront of innovation in the field of biologics. With a proprietary chemical technology platform, Xprochem helps bio-pharma partners design and create therapeutic, vaccine, and diagnostic mid-size proteins. Their goal is to make bio-pharmaceuticals more accessible and improve their effectiveness.

The Xprochem team consists of individuals with a unique combination of scientific and business expertise, ensuring a comprehensive approach to their work. They prioritize their clients' needs and consider them as partners, working closely with them to develop tailored solutions. Xprochem prides itself on reliability, building trust by sharing their clients' passion and ambitions and bringing in new skills and ideas.

They are responsive and adaptable, understanding that changes are common in pharmaceutical projects. With their advanced synthesis technology, Xprochem pushes the boundaries of peptide chemical synthesis, producing mid-size proteins without isoforms, endotoxins, or biological contaminants. The company is approved by the French Ministry of Higher Education, Research and Innovation and offers tax credits for research and development work.

Xprochem is dedicated to helping their clients achieve their goals and is the preferred partner for co-developing mid-size protein APIs, from early stages to clinical success